Inventiva vs InMed Pharmaceuticals
IVA and MTRI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IVA and MTRI compare
InMed Pharmaceuticals scores higher on the StockData Score (4 against 1 for Inventiva), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IVA | MTRI |
|---|---|---|
| Size and price | ||
| Share price | $3.68 | $18.60 |
| Change, 1 year | −9.1% | 7.5% |
| Change, 5 years | −72.1% | −99.8% |
| Beta (5Y) | 0.83 | 2.21 |
| Employees | 77 | 6 |
| StockData Score | ||
| Total score | 1 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −51.3% | – |
| Revenue growth, 5Y average | 64.5% | – |
| Profitability | ||
| Operating margin | −3146% | – |
| Return on equity | – | −253% |
| Financial health | ||
| Interest coverage | −0.7× | – |
| Current ratio | 3.81 | – |
| Piotroski F-score | – | 1 |
| Ownership | ||
| Held by institutions | 45.2% | 49.1% |
| Held by insiders | 24.7% | – |
| Insider net buying, 12 months | – | $1.4M |
Go deeper
- IVA stock overview
- IVA income statement
- IVA valuation and score
- MTRI stock overview
- MTRI income statement
- MTRI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.